Relmada Therapeutics Inc (NASDAQ:RLMD) — Market Cap & Net Worth
Market Cap & Net Worth: Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc (NASDAQ:RLMD) has a market capitalization of $798.21 Million ($798.21 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10171 globally and #2582 in its home market, demonstrating a 5.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Relmada Therapeutics Inc's stock price $7.64 by its total outstanding shares 104888233 (104.89 Million). Analyse Relmada Therapeutics Inc cash flow conversion to see how efficiently the company converts income to cash.
Relmada Therapeutics Inc Market Cap History: 2015 to 2026
Relmada Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.05 Billion to $801.35 Million (-6.75% CAGR).
Index Memberships
Relmada Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #274 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1017 of 3165 |
Weight: Relmada Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Relmada Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Relmada Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RLMD by Market Capitalization
Companies near Relmada Therapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Relmada Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Relmada Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Relmada Therapeutics Inc's market cap moved from $1.05 Billion to $ 801.35 Million, with a yearly change of -6.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $801.35 Million | +58.18% |
| 2025 | $506.61 Million | +828.85% |
| 2024 | $54.54 Million | -87.44% |
| 2023 | $434.24 Million | +18.62% |
| 2022 | $366.06 Million | -84.51% |
| 2021 | $2.36 Billion | -29.75% |
| 2020 | $3.36 Billion | -17.77% |
| 2019 | $4.09 Billion | +747.83% |
| 2018 | $482.49 Million | +53.33% |
| 2017 | $314.66 Million | -31.19% |
| 2016 | $457.31 Million | -56.40% |
| 2015 | $1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Relmada Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $798.21 Million USD |
| MoneyControl | $798.21 Million USD |
| MarketWatch | $798.21 Million USD |
| marketcap.company | $798.21 Million USD |
| Reuters | $798.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more